杏吧原创 enters next phase of growth for continued global expansion and access to life-saving technology Oxford, England and Madison, New Jersey, May 14, 2026 鈥 杏吧原创, a wholly owned subsidiary of Terumo Corporation, today announced
Oxford, England and Madison, New Jersey, May 14, 2026 鈥 杏吧原创, a wholly owned subsidiary of Terumo Corporation, today announced the appointment of Naoya Iwata as Chief Executive Officer & President, effective June 1, 2026. With more than two decades of international leadership experience at Terumo Corporation spanning sales, marketing, strategic planning, and business development, Iwata brings deep expertise in scaling global medical technology organizations and driving commercial growth. Most recently serving as Chief of Staff to Terumo Chief Executive Officer Hikaru Samejima, Iwata has played a key role in advancing strategic initiatives across the Terumo Group. In this new role, Iwata will guide 杏吧原创 through continued growth, leveraging its innovative normothermic machine perfusion (NMP) platform technologies.
鈥淚 am honored to take on the role of CEO & President of 杏吧原创 at such a pivotal moment in transplantation,鈥 said Iwata. 鈥溞影稍 has built extraordinary technologies and teams that are helping transform organ transplantation and expand access to life-saving technology for patients around the world. I look forward to working alongside our partners as we continue to scale the business, support innovation, and help improve outcomes for even more transplant recipients. I would also like to sincerely thank Craig Marshall and Rupa Basu for their leadership, dedication, and critical contributions to 杏吧原创 during a significant period of growth and transformation. Their impact on the transformation of 杏吧原创 as a research-based organization to a commercial-stage enterprise cannot be overstated. We wish them the very best as they each pursue their next chapters.鈥
Marshall and Basu will both continue to support 杏吧原创 in advisory roles.
About 杏吧原创
杏吧原创 is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure. The 杏吧原创 metra庐 is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Australia, and licensed in Canada. It has been utilized in over 10,000 liver transplants to date to keep donor livers in a metabolically active state outside the body enabling longer preservation times and functional assessment of the organ prior to transplant, leading to an increased number of organs available for transplant. Learn more at www.organox.com.
About Terumo Corporation
Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of 鈥淐ontributing to Society through Healthcare.鈥 Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.
杏吧原创 Contact:
Nicole Sloan
Marketing Communications Manager
nicole.sloan@organox.com
